Trials / Completed
CompletedNCT02743221
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Institut de Recherches Internationales Servier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for unresectable metastatic colorectal cancer in patients non-eligible for intensive therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trifluridine/tipiracil + bevacizumab | Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion. |
| DRUG | Capecitabine + bevacizumab | Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion. |
Timeline
- Start date
- 2016-04-29
- Primary completion
- 2018-01-15
- Completion
- 2020-09-01
- First posted
- 2016-04-19
- Last updated
- 2024-08-20
- Results posted
- 2019-04-16
Locations
57 sites across 12 countries: Australia, Belgium, Brazil, Denmark, France, Germany, Italy, Netherlands, Poland, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02743221. Inclusion in this directory is not an endorsement.